Article ; Online: Monoclonal antibody therapies in the management of SARS-CoV-2 infection.
Expert opinion on investigational drugs
2022 Volume 31, Issue 1, Page(s) 41–58
Abstract: Introduction: Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single ... ...
Abstract | Introduction: Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants. Areas covered: This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges associated with the use of these agents. Expert opinion: NAbs offer an effective, evidence-based therapeutic intervention during the early stages of SARS-CoV-2 infection when viral replication is the primary factor driving disease progression. As the pandemic progresses, appropriate use of NAbs will be important to minimize the risk of escape variants. Ultimately, the availability of effective treatments for COVID-19 will allow the establishment of treatment algorithms for minimizing the substantial rates of hospitalization, morbidity (including long COVID) and mortality currently associated with the disease. |
---|---|
MeSH term(s) | Antibodies, Monoclonal/therapeutic use ; Antibodies, Neutralizing/therapeutic use ; COVID-19/complications ; Humans ; SARS-CoV-2 |
Chemical Substances | Antibodies, Monoclonal ; Antibodies, Neutralizing |
Language | English |
Publishing date | 2022-02-14 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 1182884-5 |
ISSN | 1744-7658 ; 0967-8298 ; 1354-3784 |
ISSN (online) | 1744-7658 |
ISSN | 0967-8298 ; 1354-3784 |
DOI | 10.1080/13543784.2022.2030310 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3739: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.